Partner Spotlight

A Shared Vision for Next-Generation Solutions for Wet Age-Related Macular Degeneration (AMD)

Therapeutic area
- **Ophthalmology**

Product
- **TheraPEA™ polyester amide platform**

Capabilities
- **Biomaterials expertise**
- **Co-development**
- **Technical support**

Partnering for the challenge

As a world leader in eye care, our partner is currently focusing their efforts on long-acting therapies that improve the treatment landscape for patients living with wet AMD through small-molecule kinase inhibitors.

Due to the challenging nature of delivery to the back of the eye with these types of molecules, this treatment requires a delivery system that enables sustained release.

Why it matters

One of the leading causes of vision impairment is wet or dry age-related macular degeneration (AMD), a chronic condition that requires lifelong maintenance. Wet AMD is caused by damage to the macula from abnormal blood vessel growth in the back of the eye and, although wet AMD has a lower occurrence when compared to dry AMD, it results in faster loss of vision.[1]

Our innovation

The chemical nature of TheraPEA™ technology makes it the ideal excipient for drug delivery solutions in ophthalmology[3]:

BIOCOMPATIBLE
Excellent biocompatibility with the ability to tune degradation rate and optimal resorption time

ROBUST
More robust than polyesters in formulation and melt processing with nucleophilic APIs

LONG-LASTING
Enables the potential for long-lasting therapies

Our impact

Our partner developed their state-of-the-art delivery technology using our TheraPEA™ material as the delivery vehicle.

As a result, they continue to make advancements in therapies based on proven molecules using our delivery platform to develop next-generation solutions for wet AMD patients across the globe.[2]

dsm-firmenich

References: 1. Age-related macular degeneration (AMD). National Eye Institute. Updated June 22, 2021. Accessed May 28, 2024. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration **2.** Mihov G. Overcoming challenges with formulation of nucleophilic APIs in the development of long-acting therapies. dsm-firmenich. 3 data on file at dsm-firmenich

© dsm-firmenich 2024. All rights reserved.

LEARN MORE ABOUT PARTNERING WITH US AT
www.dsm-firmenich.com/biomedical